Soohyun Park

LG Life Sciences

LG Life Sciences began research in genetic engineering in 1981 and has invested steadily in the life sciences ever since. This effort has already resulted in world-class technology and product capabilities. The company has focused R&D resources and know-how on three areas-pharmaceuticals, animal health and specialty chemicals. LG Life Sciences has developed and commercialized an array of pharmaceuticals over the years. These include interferon in 1989 (Intermax-gamma) and 1992 (Intermax-alpha), hepatitis B vaccine in 1992 (EUVAX B™), human growth hormone in 1993 (EUTROPIN™), degenerative arthritis treatment in 2005 (HYRUAN Plus™), rhFSH (recombinant human follicle stimulating hormone) in 2006 (Follitrope™), and SR-hGH (Sustained Release-human Growth Hormone) in 2007 (Declage™). A company milestone was reached in 2003, when its next-generation quinolone antibiotic (FACTIVE®) was approved by the FDA in the United States. LG Life Sciences has a vision to become a "top-tier life sciences company with world-class new drugs". To this end, LGLS is expanding its strategic alliances and fostering its capabilities to identify candidate drugs for development. Indeed, the company's development of new medicines is accelerating and marketing competencies are being focused on advanced markets. In the future, LG Life Sciences will remain a leader in life sciences and biotechnology-value added areas that are knowledge intensive.